

Date: 12-08-2025

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Subject: Outcome of Board Meeting held on Tuesday, 12th August, 2025.

Ref.: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/Madam,

This is to inform that Board of Directors of the Company in its meeting held on **12th August, 2025** at the corporate office of the company i.e., House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032, which commenced at 5:00 P.M. has considered and approved:

1. The Unaudited Financial Results of the company for the quarter ended 30th June, 2025 along with the Limited Review Report of the auditors thereon.
2. The Board Report along with all other necessary Annexure for the financial year ended March 31, 2025.
3. The Draft Notice for convening the Annual General Meeting (AGM).
4. The 32nd Annual General Meeting of the Company to be convened on, Friday, 12th September 2025 at 03:00 P.M., through Video Conferencing/ Other Audio Visual Means (OAVM) in compliance with the applicable provisions of the Companies Act, 2013 read with MCA General Circulars in this regard.
5. Closure of the Register of members and share transfer books of the Company from Saturday 06th September, 2025 to Friday 12th September, 2025 for holding Annual General Meeting.
6. Appointment of M/s. Mahendra Khandelwal & Company, Practicing Company Secretary (Membership No.: 6266), as the Scrutinizer to Scrutinize the Voting through "Remote E voting" and "E- voting during the AGM" for ensuing Annual General Meeting.
7. Cut-off date for determining the eligibility to vote by electronic means for the purpose of Annual General Meeting shall be Friday 05th September, 2025.
8. Subject to the approval of the members the Board has approved and recommend special resolution for the matter of increase in the limit of investments/providing Guarantee to any Body Corporate, Bank or Financial Institute up to Rs. 500 Crore (Rupees Five Hundred Crore) under section 186 and other applicable provisions, if any, of the Companies Act, 2013.

Mahendra





Astral Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 I Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

9. Subject to the approval of the members the Board has approved special resolution for the matter of increase in the limit up to Rs. 500 Crore (Rupees Five Hundred Crore), of loans, investments, guarantee or security under section 185 and other applicable provisions, if any, of the Companies Act, 2013.
10. Subject to the approval of the members the Board has approved and recommend special resolution for the matter of increase in Borrowing power of the Company up to Rs. 500 Crore (Rupees Five Hundred Crore) pursuant to Section 180(1){c} and other applicable provisions, if any, of the Companies Act, 2013.
11. Subject to the approval of the members the Board has approved and recommend special resolution for the matter of creation of mortgage or charge on the assets, properties or undertaking(s) of the Company pursuant to Section 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013.
12. Authorized Mr. Sudheer Karna Kankanala Whole Time Director of the Company to discuss the Acquisition Proposal of Sriven Pharmachem India Private Limited.
13. The allotment of 939930 equity shares of the face value of Rs. 10 each at an issue price of Rs. 40/- each (including a premium of Rs. 30/- per share), fully paid-up upon exercising the option available with warrant holders (person belonging to promoter & non promoter category who have paid Rs. 30/- per warrant i.e. the remaining 75% of issue price) to convert 939930 warrants out of 3729930 warrants allotted on 27th November, 2024 on preferential basis through Special resolution passed by the shareholders of the Company at the Annual General Meeting held on 05th August, 2024 and In-Principle approval received from the BSE Limited vide letter no. LOD/PREF/TT/FIP/1317/2024-25 dated 14th November, 2024.

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is attached herewith as annexure I.

The Meeting was concluded at 05:30 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you
Yours sincerely,

For Astal Laboratories Limited

Mahendra Kumar

Mahendra Kumar
(Company Secretary & Compliance Officer)

Membership No.: A71224



Annexure I

Details as required as per Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015:

1. **Type of securities proposed to be issued-** Equity Shares upon conversion of Warrants.
2. **Type of Issuance-** Preferential issue to Non promoters.
3. **Total Number of Equity Shares Allotted:** 9,39,930 Equity Shares issued upon conversion of equal number of Warrants (face value of Rs. 10/-) @ Rs. 40 each.
4. **Names of the allottees of Equity Shares:**

Sr. No.	Name of the Allottees	No. of Equity Shares allotted
	Strategic Investors (Non- Promoters)	
1.	DORADLA RADHA KRISHNA (HUF)	200000
2.	MURTHY KOLLA V S S R	10000
3.	R VIJAYA SHANTHI	45000
4.	BUKKA NIRANJAN KUMAR	100000
5.	BUKKA NAGA VENKATA SATISH GUPTA	100000
6.	SAGAR PRAFUL SHAH	100000
7.	NEHA SAGAR SHAH	100000
8.	DORADLA RANGA RAO	20000
9.	TANKALA LAKSHMI GAYATRI PRAVALLIKA	30000
10.	HARISH KOMMERA	117000
11.	SESHA SAI NIKHIL CHINTALAPATI	117930

5. Post Allotment of Equity Shares:

- **Outcome of Subscription-** The Company has received (remaining 75%) Rs. 28197900.00/- (Rupees Two Crore Eighty-one Lakhs Ninety-Seven Thousand Nine Hundred) on allotment of 9,39,930 (Nine-Lakhs Thirty-Nine Thousand Nine Hundred Thirty) Equity Shares upon conversion of 939930 warrants out of 37,29,930 warrants allotted on 27th November, 2024. (Issue price of Rs. 40/- per equity share)
- **Issue Price/ Allotted Price-** Issue price of Rs. 40/- each (Face Value Rs. 10/- each + Premium Rs. 30/- each)
- **Number of Investors- 11**

Consequent to the aforesaid allotment of 9,39,930 (Nine-Lakhs Thirty-Nine Thousand Nine Hundred Thirty) Equity Shares; the paid-up equity capital of the Company has increased from

maherd





Astral Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

98,300,700.00/- consisting of 98,30,070 Equity Shares of Rs. 10/- each to Rs. 10,77,00,000.00/- consisting of 10,770,000 Equity Shares of Rs. 10/- each.

6. In case of convertibles-Intimation on conversion of securities or on lapse of the tenure of the instrument: Intimation on conversion of securities.

mahesh





Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 I Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE 2025

Sr. No	Particulars	Rs. (In Lakhs) Except EPS			
		3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	Year ended
		30/06/2025 Unaudited	31/03/2025 Audited	30/06/2024 Unaudited	31/03/2025 Audited
1	Revenue				
	a) From operations	2,532.66	2,346.67	1,314.57	6,423.10
	b) Other Income (Refer to Note No.3)	5.61	3.50	3.42	12.51
	Total Revenue	2,538.27	2,350.17	1,317.99	6,435.61
	Expenses				
2	(a) Cost of Material Consumed	2,308.22	2,484.49	1,159.12	6,181.42
	(b) Purchases of stock-in-trade		-	-	
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(161.63)	(649.20)	(166.20)	(1,370.22)
	(d) Employees Benefits expenses	44.72	9.08	40.76	133.85
	(e) Finance Cost	30.08	26.58	6.29	70.07
	(f) Depreciation and amortization expenses	12.01	10.41	1.28	22.31
	(g) Other Expenses	25.59	83.95	42.90	200.42
	Total Expenses	2,258.99	1,965.32	1,084.15	5,237.86
3	Profit/(Loss) from ordinary activities before exceptional items (1 - 2)	279.28	384.85	233.84	1,197.75
4	Exceptional Items - Income/(Expenses)	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax (3 - 4)	279.28	384.85	233.84	1,197.75
6	Tax Expenses				
	(a) Current Tax	45.61	111.48	62.29	294.08
	(b) Deferred Tax	24.71	(1.10)	2.64	11.14
7	Profit/(Loss) for the period (5 -6)	208.96	274.48	168.91	892.53
	Other Comprehensive Income				
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss (net of tax)				
	(ii) Income Tax relating to items that will be	-	-	-	-

Indhy





Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 I Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: mcil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

	reclassified to profit or loss	-	-	-	-
9	Total Comprehensive Income, net of tax (7 + 8)	208.96	274.48	168.91	892.53
10	Paid up equity share capital (Face Value of Rs.10/- each)	984.56	984.56	984.56	984.56
11	Earning per share (of Rs.10/-each) not annualised				-
	(a) Basic	2.126	2.802	1.716	9.080
	(b) Diluted	1.737	1.765	1.716	8.043
NOTES:					
1	The above Unaudited Financial Results of the company for the quarter ended June 30th 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 12 th August, 2025.				
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).				
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.				
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016				
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.				
6.	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/				

By the order of the Board
For Astal Laboratories Limited



SUDHEER KARNA KANKANALA

Whole Time Director

DIN: 07591466

Date: 12/08/2025

Place: Hyderabad

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Astal Laboratories Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of Astal Laboratories Limited for the quarter ended on 30th June, 2025, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.




Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S



S.S.Prakash
Partner
M.No.202710



UDIN : 25202710BMKWZJ2277

Place: Hyderabad
Date: 12-08-2025